Tyra Biosciences, Inc. — Director's Dealing 2021

Sep 15, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Tyra Biosciences, Inc. (TYRA)
CIK: 0001863127
Period of Report: 2021-09-14

Reporting Person: Harris Todd (Director, Chief Executive Officer)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1662336	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A Preferred Stock	$0.00		Common Stock (34007)		Direct
Stock Option (Right to Buy)	$2.25	2031-03-09	Common Stock (178202)		Direct
Stock Option (Right to Buy)	$2.25	2031-03-09	Common Stock (429012)		Direct

Footnotes

F1: Includes 464,088 shares subject to repurchase by us, which are subject to vesting.

F2: The shares of Series A Preferred Stock are convertible, at any time, at the holder's election, to shares of the Issuer's common stock at a ratio of 1-for-2.5974. In addition, effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A Preferred Stock will automatically convert to shares of the Issuer's common stock at a ratio of 1-for-2.5974. The Series A Preferred Stock has no expiration date.

F3: 1/48th of the shares subject to the option vest monthly following March 5, 2021, the vesting commencement date.

F4: 1/48th of the shares subject to the option vest monthly following March 5, 2021, the vesting commencement date.